Denied Infusion Administration Appeals: Outcomes

The infusion or injection administration service billed alongside a physician-administered drug — the professional work of giving it, distinct from the drug's own supply code.

What the independent reviewers decided

86%

overturned by the independent reviewer

of 29 decisions in the corpus

Source

California DMHC independent medical review determinations, 2017-2026. Public record.

Read this as a base rate, not as your odds

These are decisions about other patients, in one state, that had already been through the plan's own internal appeal and were then sent to an outside reviewer. That population is self-selected toward disputes worth pursuing, so the rate says what happened to cases like this at that stage — not what will happen to a specific claim. It is not medical or legal advice.

Why plans deny drug administration

The administration is bundled into another service paid the same day.
The drug itself was denied, so the administration is denied with it.
The units billed exceed what the policy allows for the infusion time documented.
The setting is disputed, with the plan directing administration elsewhere.

What actually carried the cases that won

Prior treatment appeared in 92% of the reversals and failed conservative treatment in 60% — figures that look odd for a service code until you see what they mean. These disputes were almost never about the act of infusing; they were about whether the underlying therapy was warranted, and the record that carried them was the therapy history. The practical consequence is that an administration denial is usually answered by appealing the drug, with the administration following it. This is the smallest sample of the guides we publish.

What the record showed	Share of overturned decisions
Prior treatment was documented	92%
Conservative treatment was documented as failed	60%
The severity or urgency was documented	36%
A published guideline supported the request	32%
The condition was documented as chronic or long-standing	28%
The diagnosis was confirmed	24%
The functional impact on the patient was documented	4%

Shares are of the overturned decisions and do not sum to 100% — a single decision often rested on more than one, and some rested on none of these.

What the reviewers cited

Peer-reviewed literature — in 44% of the overturned decisions
Clinical guidelines — in 28% of the overturned decisions
FDA labeling — in 24% of the overturned decisions
Specialty-society criteria — in 12% of the overturned decisions

drug administration denials — frequently asked

Is a denied administration code worth appealing?

Six times in seven the denial fell: 25 reversals across 29 California determinations, the smallest base of any guide here. Twenty-nine decisions is a small base, so read that as a direction rather than a precise figure.

Should the administration be appealed on its own?

Usually not first. Prior treatment appeared in 92% of the reversals, which reflects that these disputes are decided on the underlying therapy. Establish that the drug was warranted and the administration generally follows.

What if the denial is a bundling edit?

Then it is a coding dispute, not a necessity dispute, and it is answered with the edit rationale and any applicable modifier — a different argument from the clinical one.

Source

California Department of Managed Health Care — independent medical review determinations

Denial reasons and criteria are described in plain language for reference and vary by plan and policy. This page reports what independent reviewers decided in a public California dataset; it is general information, not medical, legal, or coverage advice.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →